BioNTech (BNTX) to Release Earnings on Monday

BioNTech (NASDAQ:BNTX) is scheduled to be posting its quarterly earnings results before the market opens on Monday, May 6th. Analysts expect BioNTech to post earnings of ($0.45) per share for the quarter. Individual that wish to listen to the company’s earnings conference call can do so using this link.

BioNTech (NASDAQ:BNTX) last announced its quarterly earnings data on Wednesday, March 20th. The company reported $2.05 EPS for the quarter, missing analysts’ consensus estimates of $2.64 by ($0.59). BioNTech had a net margin of 24.26% and a return on equity of 4.60%. The firm had revenue of $1.59 billion during the quarter, compared to analyst estimates of $2.04 billion. On average, analysts expect BioNTech to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

BioNTech Trading Up 0.6 %

Shares of BioNTech stock opened at $87.21 on Monday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 9.26 and a current ratio of 9.43. BioNTech has a 52 week low of $85.21 and a 52 week high of $125.83. The stock has a 50 day moving average price of $90.77 and a two-hundred day moving average price of $96.33. The stock has a market capitalization of $20.73 billion, a PE ratio of 21.17 and a beta of 0.23.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on BNTX shares. BMO Capital Markets dropped their target price on BioNTech from $127.00 to $123.00 and set an “outperform” rating on the stock in a report on Thursday, March 21st. Canaccord Genuity Group restated a “buy” rating and issued a $171.00 target price on shares of BioNTech in a report on Thursday, March 21st. JPMorgan Chase & Co. dropped their target price on BioNTech from $99.00 to $90.00 and set an “underweight” rating on the stock in a report on Friday, March 22nd. UBS Group dropped their target price on BioNTech from $110.00 to $101.00 and set a “neutral” rating on the stock in a report on Wednesday, March 27th. Finally, The Goldman Sachs Group dropped their target price on BioNTech from $113.00 to $100.00 and set a “neutral” rating on the stock in a report on Wednesday, February 28th. One analyst has rated the stock with a sell rating, five have given a hold rating and four have issued a buy rating to the company. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $120.40.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.